World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering
By adding Canada and the entire Latin America region, including Mexico, WODA completes its full global commercialization offering for rare and ...
Rigel Pharma: FDA Grants Orphan Drug Designation To R289 - Quick Facts
Rigel Pharmaceuticals (RIGL) announced the FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic ...
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
Drug to treat rare pediatric disease accepted for FDA review
A subsidiary of a Miami-based company is inching closer to FDA approval for a drug that treats a rare pediatric disease.
Numiera Therapeutics Announces Orphan Drug Designation and Matching Funds from the State of Colorado to Advance Innovative Brain Cancer Treatment
About Numiera Therapeutics Numiera is a preclinical-stage pharmaceutical company focused on developing small-molecule ...
Healio2d
Cour Pharmaceuticals snags orphan drug designation for CNP-104 for the treatment of PBC
The FDA has granted Cour Pharmaceuticals orphan drug designation for CNP-104, a biodegradable nanoparticle in development for ...
New drug for prostate cancer patients in clinical trials
Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...
COUR Pharmaceuticals Secures FDA Orphan Drug Designation for CNP-104 in Primary Biliary Cholangitis
COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed ...
Targeted Oncology2d
Amezalpat Gains FDA Orphan Drug Status in HCC
The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...
Rigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289
Rigel Pharmaceuticals on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to its proposed R289 treatment for myelodysplastic syndromes, a group of rare blood cancers ...
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...